Navigation Links
The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
Date:10/30/2008

DOYLESTOWN, Pa., Oct. 30 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY), http://www.quigleyco.com today reported net sales from continuing operations of $6.4 million, for the third quarter ended September 30, 2008, compared to $9.1 million reported for the third quarter ended September 30, 2007. For the nine months ended September 30, 2008, net sales were $13.7 million compared to $17.5 million reported for the nine months ended September 30, 2007.

The third quarter and nine month periods of 2008 reflect a net sales decrease as a result of a slow start to the 2007/2008 cold season and changes to customers' buying habits. The 2008 periods' net sales were favorably offset by sales of the Kids-EEZE(R) Chest Relief product line, which was launched in August 2008 and a price increase which commenced in the third quarter of 2007. Kids-EEZE(R) Chest Relief, http://www.kids-eeze.com is a single-ingredient, allopathic expectorant with guaifenesin to help children, ages six and up, suffering from uncomfortable chest congestion. Kids-EEZE(R) Chest Relief provides an alternative to the many multi-symptom children's cold products that could potentially lead to overmedication. The Company has initiated an advertising and targeted couponing campaign to promote the COLD-EEZE(R) brand and brand extensions during the forthcoming cold season.

Income from continuing operations for the third quarter ended September 30, 2008 was $879,000, or $0.07 per share, compared to $1.4 million, or $0.11 per share for the third quarter of 2007. Loss from continuing operations for the nine months ended September 30, 2008, was $4.4 mill
'/>"/>

SOURCE The Quigley Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
2. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
3. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
4. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
5. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
6. Brooke Franchise Corporation Announces Selected July Results
7. MedThink Communications Retained by NanoBio Corporation
8. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
9. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
10. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
11. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...ers from the North Pole, Textsanta.net lets parent...a , North Pole, AK (PRWEB...cies at the North Pole Santa Claus has added SMS t...lobe informed of his Christmas progress at the Nor...tment have identified a large and growing percenta...
(Date:11/26/2009)...angle Dental (RTDental), a leading dental group pr...the expansion of its services to include LUMINEERS...an. , Durham, NC (PRWE...nce that Dr. Doug Macmillan, an experienced LUMIN...vanced training seminar. RTDental’s ability...
(Date:11/26/2009)...Ennis, P.A. is offering free nationwide confidenti... control pills who have suffered a Deep Vein Throm...ack or other related cardiac issues or had their G...800-856-6405 or go to the firm’s website at ...ase evaluation form. , (P...
(Date:11/25/2009)... The Bartle Hall Convention Center...cal clinic on Dec. 9-10, when Kansas City hosts th...ninsured people. ,, "This free clinic event has...it will extend over two days instead of just one a... Sheri Wood, executive director of the Kansas City...
(Date:11/25/2009)... 25 /PRNewswire/ - Sentinelle Medical Inc., a lead...I) coils and software and Calgary Scientific Inc.,...ies, have introduced a web version of Aegis(TM) Br...s innovative interface is the first truly zero-foo...n the market. Calgary Scientific,s PureWeb(TM) pla...
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3
... Oct. 29, 2008 The Procter &,Gamble Company (NYSE... for,the July - September quarter to $22.0 billion...t the mid-point of the Company,s four to six perce...gs,per share increased 12 percent to $1.03 for the...
....J., Oct. 29 ConvaTec, a world-leading,developer ...r community and,hospital care, today announced tha...ent of the company,s Wound Therapeutics Business U... of four new,operating divisions -- Ostomy Care, W...
...a Sustainable Transition with SafePath,s ADA Appro...versal Voter Access, CHICO, Calif., Oct. 29 For ...isability, casting their ballot is not just,a deci...ions of voting American,s will be left to determin...
... After over 25 years of crafting sm...n selected for the 2008 Best of San Diego Award in.... based U.S. Local Business Association (USLBA). ...selected for the 2008 Best of San Diego Award in t...
... Global biochips market is forecast...each $3.4 billion by 2012. Aging population, third...viduals suffering from common chronic diseases rep... afforded by biochips have created a holistic mean...
... Lloydspharmacy campaign against th... Family star Ricky Tomlinson , ...inson has warned British men against the threat of... past and paid the price in 2007 when he was diagn...
Other Medicine News:Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 2Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 3Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 4Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 5Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 6Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 7Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 8Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 9Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 10Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 11Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 12Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 13Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 14Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 15Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 16Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 17Health News:ConvaTec Names Presidents of Wound Therapeutics and Ostomy Care Business Units 2Health News:SafePath(TM) Products Provides Universal Access for Ohio Voters 2Health News:Dr. Ron Greenspan has Been Selected for the 2008 Best of San Diego Award in the Orthodontists Category by the U.S. Local Business Association 2Health News:Dr. Ron Greenspan has Been Selected for the 2008 Best of San Diego Award in the Orthodontists Category by the U.S. Local Business Association 3Health News:World Biochips Market to Reach $3.4 billion by 2012, According to New Report by Global Industry Analysts, Inc. 2Health News:World Biochips Market to Reach $3.4 billion by 2012, According to New Report by Global Industry Analysts, Inc. 3Health News:Ricky Tomlinson Joins Lloydspharmacy Against Coronary Heart Disease 2Health News:Ricky Tomlinson Joins Lloydspharmacy Against Coronary Heart Disease 3
(Date:11/25/2009)... , WEST PALM BEACH, Fla., Nov. 25 /PRNewsw...ing impaired Americans, especially the 27 million ... may not be all that happy, says audiologist Cindy...HearUSA (Amex: EAR ), one of America,s largest he...ies have linked hearing loss to stress, frustratio...
(Date:11/25/2009)... , BASKING RIDGE, N.J., Nov. 25 /PRNewswire...leading the development of antithrombotic aptamers...Mazzo, PhD, CEO and President, will be presenting ...rence at the New York Palace Hotel in New York Cit...pm (EST) on Tuesday, December 1 and will include a...
(Date:11/25/2009)... , NEW YORK, Nov. 25 R...ch report is available in its catalogue: ,, M... ,, http://www.reportlinker.com/p0164330/Mam...tml ,, Rising incidence of breast cancer in in...incipal factor influencing growth in the mammograp...
Breaking Medicine Technology:For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8Black Activist Speaks Out Against Race Preferences in Health Care Bill 52514 1Black Activist Speaks Out Against Race Preferences in Health Care Bill 52514 2AlphaRx Presents Positive Preclinical Data on Zysolin 28TM 29 Inhalable Nanoparticles at Controlled Release Society Annual Meeting 52512 1AlphaRx Presents Positive Preclinical Data on Zysolin 28TM 29 Inhalable Nanoparticles at Controlled Release Society Annual Meeting 52512 2AlphaRx Presents Positive Preclinical Data on Zysolin 28TM 29 Inhalable Nanoparticles at Controlled Release Society Annual Meeting 52512 3Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 1Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 2Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 3Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 4Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 5Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 6Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 7Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 8Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 9Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 10Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 11Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 12Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 13Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 14Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 15Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 16Sigma Aldrich 28Nasdaq 3ASIAL 29 Reports Q2 2009 Diluted EPS of 240 68 3B YTD Diluted EPS up 1 5 25 to 241 36 Full Year 2009 Guidance Reaffirmed 13165 17
...erability of TAXUS(R) Liberte(R) drug-elu...ICK, Mass. and WASHINGTON, Oct. 22 Boston,Scienti...-month data from the,pivotal TAXUS ATLAS Small Ves...XUS(R) Liberte(R) Paclitaxel-Eluting Stent System ...t significantly reduced restenosis and,maintained ...
...ty, Consistently Positive Clinical ...22 Data presented today from,Abbott,s SPIRIT III ...,positive, statistically significant clinical resu...ry Stent System at one year, including continued,c...s (MACE) and continued,non- inferior rates of targ...
Other Medicine Technology:Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions 2Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions 3Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions 4Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions 5Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 2Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 4Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 5
DErrico Perforator Drill and Enlarging Burr
Cushing Perforator Drill
Doro J-Arm Retractor System
Spoon End Periosteal
Medicine Products: